Bansal Wire Industries Ltd. Share Price

Key News & Earnings Updates

Bansal Wire is finally waking up after a long period of sideways movement. The stock spent nearly two and a half months—stretching from April through mid-June—trapped in a tight consolidation zone. As an analyst, what excites me is the weekly "inside bar" breakout. It stayed coiled for seven weeks before snapping upward, backed by a significant surge in volume. Whether you view this as a trendline breach or a flag breakout, the conclusion is the same: the momentum has shifted. view: This is a textbook "buy on strength" scenario. The fact that it consolidated for so long means the subsequent move is likely to be sustainable rather than a flash in the pan. The risk-reward ratio here is incredibly favorable for July.

Bansal Wire Industries Ltd – Fundamental Analysis

Bansal Wire Industries and Emcure Pharmaceuticals remained in focus on June 25 following major stake sales, with institutional investors emerging as key buyers in both companies. In Bansal Wire Industries, promoter group member Mrinaal Mittal sold 46.82 lakh shares, equivalent to a 2.99% stake, through an open market transaction valued at Rs 144.7 crore. Ahead of the transaction, Mrinaal Mittal had informed the stock exchanges on June 24 about his intention to divest up to 2.99% of his holding to comply with the minimum public shareholding (MPS) requirement. As of March 2026, the promoter group owned 77.99% of the company. The stake sale was absorbed by four institutional investors—HDFC Mutual Fund, Invesco Mutual Fund, BNP Paribas Financial Markets, and Malabar India Fund. Shares of Bansal Wire ended the day nearly unchanged, closing 0.02% lower at Rs 314.9 on the National Stock Exchange. Meanwhile, Emcure Pharmaceuticals also witnessed a significant block deal involving private equity investor Bain Capital. The latest transaction marked Bain Capital's third stake sale in the current quarter. Earlier, it sold 36 lakh shares worth Rs 612 crore on June 9 and another 18 lakh shares worth Rs 289.47 crore on April 29. Across the three transactions, Bain Capital has offloaded 73.39 lakh shares, representing a 3.87% stake, effectively exiting its entire holding in Emcure Pharmaceuticals, based on its shareholding as of March 2026.

Bansal Wire Industries Announces Q4FY26 Investor Presentation Under SEBI Regulation 30